United States-Abraham Accords Cooperation and Security Act of 2025

H.R. 1794 would amend federal food and drug law to create an Abraham Accords Office within the Food and Drug Administration. This office would work to promote and facilitate cooperation between the FDA and entities from countries that have signed the Abraham Accords—diplomatic agreements that established normalized relations between Israel and several Middle Eastern nations including the United Arab Emirates, Bahrain, Morocco, and Sudan.

The bill would enable companies and organizations from these Abraham Accords countries to more easily work with the FDA to develop and sell pharmaceutical, medical device, and cosmetic products in the United States. By streamlining regulatory cooperation, the legislation would aim to increase trade and commercial partnerships in the health and medical sectors between the United States and these nations.

The bill is currently in committee and has not yet been voted on by the full House. If enacted, it would primarily affect pharmaceutical companies, medical device manufacturers, and cosmetic producers from Abraham Accords countries seeking to enter the U.S. market, as well as American companies looking to collaborate with counterparts in these regions.